ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Reagan Signs Appropriations Bill, Vetoes Biomedical Research Authorization Measure; Capitol Hill Angry

November 16, 1984

No Evidence Of Fraud Found In NCI Audit Of NSABP Trials

April 29, 1994

Heart Institute Withdraws Sponsorship Of Breast Cancer Prevention Trial

October 27, 1995

In Brief: Stipends Out For Trainees In new Clinical Program, But They Can Be Paid If Any Money Is Available

May 31, 1974

NCAB, President’s Cancer Panel honor the late Paul Calabresi.

June 11, 2004

Still Misperceptions On Hill About CRADA Between NCI, BMS

March 13, 1992